Abstract A276: Phase 1 multicenter, open label, dose-escalation study of LEE011, an oral inhibitor of cyclin-dependent kinase 4/6, in patients with advanced solid tumors or lymphomas.
The DOI matches its Crossref record.
Abstract
Abstract Background: LEE011 is an oral small molecule inhibitor with highly specific nanomolar inhibitory activity against CDK4/cyclinD1 and CDK6/cylinD3 complexes. Preclinical studies with LEE011 have demonstrated robust anti-tumor activity in several tumor models with functional retinoblastoma protein (pRb). Methods: The primary objective this phase 1 dose escalation study was to determine the maximum tolerated dose (MTD) based on cycle 1 dose-limiting toxicities (DLTs) and establish the recommended dose for expansion (RDE) of LEE011 in patients (pts) with pRb-positive advanced solid tumors or lymphomas. Using a Bayesian logistic regression model with overdose control principle, escalating doses of LEE011 were administered daily for 21 days of 28-day cycles. Following MTD determination, a continuous dosing schedule was also evaluated. Evaluation of safety and pharmacokinetics (PK) from all pts contributed to defining the RDE. Results: As of June 28, 2013, a total of 70 pts were treated in the escalation phase at doses from 50-1200 mg. DLTs are described in the table. MTD was defined at 900 mg on a 21 of 28-day dosing schedule. Additional patients were treated at 750 mg and 600 mg on the current schedule and at 600 mg on a continuous schedule to define the RDE and sustain optimal long-term dosing. Following review of PK and safety data, including AEs observed beyond cycle 1, the planned RDE is 600 mg for 21 days of a 28-day treatment cycle. Common adverse events (AEs) were gastrointestinal (nausea 40%, diarrhea 30%) and hematologic (anemia 43%, neutropenia 40%); the majority of AEs were grades 1/2 and reversible. Asymptomatic QTc prolongation was observed at the higher doses. LEE011 is absorbed orally with Tmax ≈ 4 hours and effective t1/2 ≈24 hours. Dose-dependent increases in exposure were observed. Preliminary evidence of activity was observed including stable disease for ≥ 6 cycles in 10/70 pts (14%) and 1 confirmed partial response in a pt with ER-positive breast cancer. Preliminary tumor pharmacodynamic data shows evidence of modulation at doses of 600 mg and above. Conclusions: LEE011, a highly selective inhibitor of CDK4/6, exhibited an acceptable safety profile, dose dependent PK, and preliminary clinical activity. Enrollment will continue in the expansion phase. Citation Information: Mol Cancer Ther 2013;12(11 Suppl):A276. Citation Format: Jeffrey R. Infante, Geoffrey I. Shapiro, Petronella O. Witteveen, John F. Gerecitano, Vincent Ribrag, Rashmi Chugh, Abhijit Chakraborty, Alessandro Matano, Xumei Zhao, Sudha Parasuraman, Philippe A. Cassier. Phase 1 multicenter, open label, dose-escalation study of LEE011, an oral inhibitor of cyclin-dependent kinase 4/6, in patients with advanced solid tumors or lymphomas. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2013 Oct 19-23; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2013;12(11 Suppl):Abstract nr A276.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Plasma exposure increases were slightly higher than dose-proportional; the mean half-life at the 600 mg dose level was 36.2 hrs.”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [90]
In the citing paper
“Partial responses were seen in a patient with PIK3CA-mutated, CCND1-amplifed, ER+ breast cancer and in a second patient with wild type BRAF/NRAS, CCND1-amplified melanoma.”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [90]
In the citing paper
“Stable disease for ≥6 cycles was observed in 14% of the treated population.”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [90]
In the citing paper
“Among paired tumor biopsies from 40 patients, reductions of ≥50% from baseline in Ki67 and phospho-pRB were documented in 55% and 42% of samples, respectively”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [90]
In the citing paper
“Among 85 patients treated, dose limiting toxicities occurred in ten, including neutropenia, thrombocytopenia, pulmonary embolism, hyponatremia, QTcF prolongation and elevated creatinine, resulting in a recommended phase 2 dose of 600 mg daily on the 3/1 schedule.”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [90]
Citations
Cites
Still being checked.
Cited by
Targeting CDK4 and CDK6: From Discovery to Therapy
Sherr, C. J., Beach, D., & Shapiro, G. I. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0894 · Cited by 936
“Other reported adverse events Anemia, nausea, anorexia, fatigue, diarrhea (69, 70) Mucositis Prolonged EKG QTc interval Elevated creatinine Nausea (90) Diarrhea Neutropenia (92)”
Self-citationPatnaik, A., Rosen, L. S., Tolaney, S. M., Tolcher, A. W., Goldman, J. W., Gandhi, L., Papadopoulos, K. P., Beeram, M., Rasco, D. W., Hilton, J. F., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0095 · Cited by 743
Self-citationTargeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers
Finn, R. S., Aleshin, A., & Slamon, D. J. (2016) · Breast Cancer Research · doi:10.1186/s13058-015-0661-5 · Cited by 368
Molecular pathways: CDK4 inhibitors for cancer therapy
Dickson, M. A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1551 · Cited by 245
Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib
Kwapisz, D. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4385-3 · Cited by 202
Metadata
- Authors
- Infante, J. R., Shapiro, G. I., Witteveen, P. O., Gerecitano, J. F., Ribrag, V., Chugh, R., Chakraborty, A., Matano, A., Zhao, X., Parasuraman, S., & Cassier, P. A.
- Affiliations
- Sarah Cannon (US)
- Dana-Farber Cancer Institute (US)
- University Medical Center Utrecht (NL)
- Memorial Sloan Kettering Cancer Center (US)
- Institut Gustave Roussy (FR)
- University of Michigan (US)
- Novartis (Switzerland) (CH)
- Centre Léon Bérard (FR)
- ORCID
- Venue
- Molecular Cancer Therapeutics
- Published
- 2013-11-01
- Volume
- 12
- Issue
- 11_Supplement
- Pages
- A276-A276
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- OpenAlex
- W2077611283
- Cited by
- 16
- References
- 0
- Citations by year
- 2021: 1 · 2018: 1 · 2017: 2 · 2016: 5 · 2015: 4 · 2014: 3
- Type
- conference abstract
- Language
- en
- Open access
- closed
- Locations
- Molecular Cancer Therapeutics (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- ribociclib, CDK4/6 inhibitors, CDK4, CDK6, cyclin D1, cyclin D3, retinoblastoma protein, advanced solid tumors, lymphoma, maximum tolerated dose, recommended dose, dose-limiting toxicity, pharmacokinetics, QTc prolongation, hematologic toxicity, gastrointestinal toxicity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Abstract A276: Phase 1 multicenter, open label, dose-escalation study of LEE011, an oral inhibitor of cyclin-dependent kinase 4/6, in patients with advanced solid tumors or lymphomas. https://app.cochat.ai/papers/10.1158/1535-7163.targ-13-a276
- The paper
- Infante, J. R., Shapiro, G. I., Witteveen, P. O., Gerecitano, J. F., Ribrag, V., Chugh, R., Chakraborty, A., Matano, A., Zhao, X., Parasuraman, S., & Cassier, P. A. (2013). Abstract A276: Phase 1 multicenter, open label, dose-escalation study of LEE011, an oral inhibitor of cyclin-dependent kinase 4/6, in patients with advanced solid tumors or lymphomas. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.targ-13-a276
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.